Skip to content

Released Nov 11, 2022, after the close

10-Q filed Nov 14, 2022, 45 days after period end · 0001390478-22-000028

Q3 2022 · 10-Q
Revenue$0.00— vs Q3 2021no prior Q2 2022 on file
Net Income-$7.02MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.34N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$7,146,000N/M
Operating Cash Flowderived-$5,746,000N/M

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$0.00$0.00$0.00—
Net Income-$7.02M-$7.09M-$4.47M-$4.20M
EPS Diluted-$0.34-$0.45-$0.53-$2.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR